A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study

Patterns of relapse and prognosis after bevacizumab (BEV) failure in recurrent glioblastoma (GBM)

(2017) A. B. Lassman et al.   JOURNAL OF CLINICAL ONCOLOGY

Large volume reirradiation as salvage therapy for glioblastoma after progression on bevacizumab

(2014) William Magnuson et al.   JOURNAL OF NEURO-ONCOLOGY

MGMT testing—the challenges for biomarker-based glioma treatment

(2014) Wolfgang Wick et al.   Nature Reviews Neurology

NT-40 * Interim Analysis of the EF-14 Trial: A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM

(2014) R. Stupp et al.   NEURO-ONCOLOGY

Veliparib hydrochloride

(2010) L.M. Lepeak et al.   DRUGS OF THE FUTURE

Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies

(2009) Shivaani Kummar et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY